Preventing deaths from cryptococcal meningitis: From bench to bedside

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 9, 2011, Pages 715-717

  Roy, Monika ^a   Chiller, Tom ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

AIDS; cryptococcus; fluconazole; HIV

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; FLUCONAZOLE; FUNGUS ANTIGEN;

AFRICA SOUTH OF THE SAHARA; AIDS PATIENT; ANTIGEN DETECTION; CAUSE OF DEATH; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS; EARLY DIAGNOSIS; EARLY INTERVENTION; ENZYME IMMUNOASSAY; FUNGUS CULTURE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOAFFINITY CHROMATOGRAPHY; LATERAL FLOW IMMUNOASSAY; LATEX AGGLUTINATION TEST; MENINGITIS; MORTALITY; POINT OF CARE TESTING; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

AFRICA SOUTH OF THE SAHARA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; COST-BENEFIT ANALYSIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; HIV; HIV INFECTIONS; HUMANS; IMMUNOASSAY; MASS SCREENING; MENINGITIS, CRYPTOCOCCAL;

EID: 80052717605     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.86     Document Type: Conference Paper

References (10)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23(4), 525-530 (2009).
2. Tanner DC, Weinstein MP, Fedorciw B et al. Comparison of commercial kits for cryptococcal antigen. J. Clin. Microbiol. 32(7), 1680-1684 (1994). (Pubitemid 24189556)
3. Lindsley MD, Mekha N, Baggett HC et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of Cryptococcosis. Clin. Infect. Dis. 53(4), 321-325 (2011).
4. Bekondi C, Bernede C, Passone N et al. Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Int. J. Infect. Dis. 10, 387-395 (2006). (Pubitemid 44209231)
5. Lawn SD, Bekker LG, Myer L, Orrell C, Wood R. Cryptococcal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral program. AIDS 19, 2050-2052 (2005). (Pubitemid 41669038)
6. Etard JF, Ndiaye I, Thierry-Mieg M et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20, 1181-1189 (2006). (Pubitemid 43786107)
7. Jarvis JN, Meintjes G, Wood R, Jarrison TS. Testing but not treating: missed opportunities and lost lives in the South African anti-retroviral therapy programme. AIDS 24, 1233-1235 (2010).
8. French N, Gray K, Watera C et al. Crytpococcal infection in a cohort of HIV-1 infected Ugandan adults. AIDS 16, 1031-1038 (2002). (Pubitemid 34499426)
9. Jarvis JN, Lawn SD, Vogt M et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin. Infect. Dis. 48, 856-862 (2009).
10. Meya DB, Manabe YC, Castelnuovo B et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4 cell count =100 cells/μl who start HIV therapy in resource-limited settings. Clin. Infect. Dis. 51, 448-455 (2010).